— Know what they know.
Not Investment Advice
Also trades as: 0QZU.L (LSE) · $vol 1M · VX1.DE (XETRA) · $vol 0M

VRTX NASDAQ

Vertex Pharmaceuticals Incorporated
1W: +1.2% 1M: -1.3% 3M: +7.8% YTD: +15.2% 1Y: +23.6% 3Y: +44.0% 5Y: +181.0%
$521.03
+3.54 (+0.68%)
Pre-Market: $528.45 (+7.42, +1.42%)
Weekly Expected Move ±4.1%
$480 $502 $524 $546 $567
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 62 · $132.1B mcap · 253M float · 0.544% daily turnover · Short 52% of daily vol
Credit Risk of going bust: lower than 94% of companies Debt: 1.5% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the safest four tenths, about 1 in 3,500 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.52 (down 99.9%), Vertex Pharmaceuticals Incorporated would be worth roughly what it owes.
Total debt $1.98B against a stock market value of $132.06B.
Distance to default 17.12 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $988.8M (short-term plus half of long-term), stock volatility 28.8%; Altman Z'' 8.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.

Balance Sheet Trends

Total Assets
$26.1B +16.0% ▲
5Y CAGR: +17.3%
Total Liabilities
$7.5B +22.1% ▲
5Y CAGR: +19.5%
Shareholders Equity
$18.7B +13.7% ▲
5Y CAGR: +16.5%
Cash & Investments
$6.6B +8.1% ▲
5Y CAGR: -0.1%
Total Debt
$3.9B +121.9% ▲
5Y CAGR: +33.0%
Net Debt
-$1.2B +57.3% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$6.8B$10.5B$10.4B$4.6B$5.1B
Short-Term Investments$730M$274M$849M$1.5B$1.5B
Cash & ST Investments$7.5B$10.8B$11.2B$6.1B$6.6B
Net Receivables$1.1B$1.4B$1.6B$1.6B$2.1B
Inventory$353M$461M$739M$1.2B$1.7B
Other Current Assets$104M$122M$86M$206M$749M
Total Current Assets$9.6B$13.2B$14.1B$9.6B$11.2B
Property, Plant & Equip.$1.4B$1.5B$1.5B$2.6B$3.1B
Goodwill & Intangibles$1.4B$1.7B$1.9B$1.9B$1.5B
Long-Term Investments$0$112M$2.5B$5.1B$5.8B
Other Non-Current Assets$111M$410M$895M$999M$1.1B
Total Non-Current Assets$3.9B$4.9B$8.6B$12.9B$14.9B
Total Assets$13.4B$18.2B$22.7B$22.5B$26.1B
— Liabilities —
Accounts Payable$195M$304M$365M$413M$462M
Short-Term Debt$0$0$0$92M$83M
Deferred Revenue$172M$160M$170M$207M$172M
Other Current Liabilities$16M$62M$51M$225M$2.7B
Total Current Liabilities$2.1B$2.7B$3.5B$3.6B$3.9B
Long-Term Debt$0$0$0$0$1.8B
Other Non-Current Liab.$303M$686M$878M$902M-$1.5B
Total Non-Current Liabilities$1.2B$1.5B$1.6B$2.6B$3.6B
Total Liabilities$3.3B$4.2B$5.1B$6.1B$7.5B
— Equity —
Common Stock$2M$3M$3M$3M$2M
Retained Earnings$3.2B$6.5B$10.1B$9.6B$13.6B
Accumulated OCI$16M$800K-$14M$128M-$16M
Total Stockholders Equity$10.1B$13.9B$17.6B$16.4B$18.7B
Total Liabilities & Equity$13.4B$18.2B$22.7B$22.5B$26.1B
— Key Metrics —
Total Debt$967M$900M$808M$1.7B$3.9B
Net Debt-$5.8B-$9.6B-$9.6B-$2.8B-$1.2B
Total Investments$730M$387M$3.3B$6.7B$7.3B

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms